Table 3 Relationships between HMGB1 expression and clinicopathological factors
Variable | HMGB1 high (n = 31) | HMGB1 low (n = 48) | P value |
|---|---|---|---|
Age | |||
 Median (range) | 68 (46–83) | 66 (42–83) | 0.42 |
Sex | |||
 Male | 11 (35%) | 24 (50%) | 0.21 |
 Female | 20 (65%) | 24 (50%) |  |
Type of pancreatectomy | |||
 PD | 23 (74%) | 22 (46%) | 0.013 |
 PpPD, SSPPD | 8 (26%) | 26 (54%) |  |
Node dissection | |||
 D1 | 12 (39%) | 12 (25%) | 0.20 |
 D2, D3 | 19 (61%) | 36 (75%) |  |
Operative time (min) | |||
 Median (range) | 490 (308–716) | 451 (0–856) | 0.3 |
Blood loss (ml) | |||
 Median (range) | 949 (150–3696) | 722 (100–3020) | 0.025 |
Transfusion | |||
 Yes | 8 (26%) | 11 (23%) | 0.77 |
 No | 23 (74%) | 37 (77%) |  |
Morbidity (grade IIIa) | |||
 Yes | 13 (42%) | 22 (46%) | 0.73 |
 No | 18 (58%) | 26 (54%) |  |
Tumor diameter (mm) | |||
 Median (range) | 20 (8–35) | 20 (8–65) | 0.074 |
Tumor ulceration | |||
 Yes | 9 (29%) | 13 (27%) | 0.85 |
 No | 22 (71%) | 35 (73%) |  |
Type of adenocarcinoma | |||
 Moderate or poor differentiated | 12 (39%) | 21 (44%) | 0.66 |
 Other types | 19 (61%) | 27 (56%) |  |
T stage (AJCC 8th) | |||
 T3a | 9 (29%) | 18 (38%) | 0.44 |
 T1a, T1b, T2 | 22 (71%) | 30 (62%) |  |
N stage (AJCC 8th) | |||
 N1, N2 | 12 (39%) | 14 (29%) | 0.38 |
 N0 | 19 (61%) | 34 (71%) |  |
Overall stage (AJCC 8th) | |||
 IIA, IIIA, IIIB | 17 (55%) | 24 (50%) | 0.67 |
 IA, IB | 14 (45%) | 24 (50%) |  |
Adjuvant chemotherapy | |||
 (−) | 20 (65%) | 31 (65%) | 1.00 |
 (+) | 11 (35%) | 17 (35%) |  |